Medication info
Gabapentin Tablets 150mg (Pregabalin)

Gabapentin Tablets 150mg (Pregabalin)

Prescription medicationTabletOral
Ingredient · strength
Pregabalin›150mg / 1 tablet
Manufacturer / importer
Samil Pharmaceutical Co., Ltd.
Appearance
White or light yellow round tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201705789 · Approved 2017.07.20 · Insurance code 643903570

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
This medicine is administered orally in 2 divided doses per day, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The recommended starting dose is 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The recommended starting dose is 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’.) 2. Epilepsy Adults: The recommended starting dose is 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The starting dose is 75 mg twice daily (150 mg/day); based on efficacy and tolerability, this may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as indicated in the dosing regimen. b: A supplemental dose refers to an additional single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Use is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Use is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Samil Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral and central neuropathic pain
  • partial seizures with or without secondary generalized symptoms
  • fibromyalgia
View approved original text

This medication is used to alleviate peripheral and central neuropathic pain in adults. It is also utilized as an adjunctive treatment for controlling partial seizures in patients with epilepsy and can be applied when there are secondary generalized symptoms. It reduces pain associated with fibromyalgia and improves the quality of life for patients. It is an effective drug for improving pain and seizure symptoms related to various neurological disorders.

How to take

Adult dose

This medicine is administered orally in 2 divided doses per day, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The recommended starting dose is 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The recommended starting dose is 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’.) 2. Epilepsy Adults: The recommended starting dose is 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The starting dose is 75 mg twice daily (150 mg/day); based on efficacy and tolerability, this may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as indicated in the dosing regimen. b: A supplemental dose refers to an additional single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Use is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Use is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication can cause mental health issues such as suicidal thoughts or behaviors, hence it is essential to closely monitor mood or behavioral changes during treatment. Those who are allergic to this drug should not take it. Diabetic patients may experience weight gain while taking this medication, which may require adjustments in the dosage of blood sugar control medications. If symptoms of angioedema appear, such as swelling of the face, mouth, or throat, the medication should be stopped immediately. Elderly patients may experience dizziness or drowsiness when taking this medication, which increases the risk of falls. Some patients may experience blurred vision or vision changes, which can improve after discontinuation of the medication. Care should be taken when switching from other antiepileptic drugs to monotherapy. Abrupt discontinuation of this medication can lead to withdrawal symptoms such as insomnia, headache, nausea, and anxiety; therefore, dosage should be tapered gradually. There is a risk of drug abuse, so patients with a history of substance abuse should be particularly cautious. Patients with impaired kidney function may require dosage adjustments of this medication. Patients with heart diseases should take this medication with caution, especially those with congestive heart failure who should be particularly careful. Co-administration with opioid analgesics may increase the risk of central nervous system depression; caution is recommended. Patients with respiratory or neurological disorders, kidney impairment, and elderly patients may have an increased risk of severe respiratory depression and may require dose adjustments. Pregnant women should avoid taking this medication during the early stages of pregnancy due to the risk of fetal malformations, and women of childbearing age should use effective contraception. This medication is excreted in breast milk; therefore, it is recommended to avoid taking it while breastfeeding. Dizziness or drowsiness may occur while driving or operating machinery, hence caution should be taken until symptoms fully resolve. If severe skin rashes or allergic symptoms occur, the medication should be stopped immediately and a healthcare provider should be consulted. In cases of overdose, symptoms such as confusion, drowsiness, depression, or seizures may occur, requiring immediate medical attention.

Side effects

  • suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral edema
  • upper airway edema
  • dizziness
  • drowsiness
Show 195 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • depression
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • weight gain
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual sensation disorder
  • agitation
  • mood swings
  • emotional blunting
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • apathy
  • ataxia
  • motor coordination abnormalities
  • balance disturbances
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory disturbances
  • sensory loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • language impairment
  • myoclonus
  • reflex latency
  • motor abnormalities
  • psychomotor agitation
  • position-induced dizziness
  • hypersensitivity
  • burning sensation
  • action tremor
  • syncope
  • confusion
  • motor decline
  • olfactory disturbances
  • taste loss
  • writing difficulties
  • diplopia
  • vertigo
  • auditory hypersensitivity
  • 1st-degree AV block
  • tachycardia
  • bradycardia
  • unclassified arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • shortness of breath
  • nasal hemorrhage
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal bloating
  • constipation
  • dry mouth
  • abdominal distension
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • joint pain
  • back pain
  • limb pain
  • cervical spasm
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • intoxicated feeling
  • altered sensation
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • elevated serum creatine phosphokinase
  • increased aspartate aminotransferase
  • elevated blood sugar
  • decreased platelet count
  • decreased serum potassium
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • congestive heart failure
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • confusion state
  • agitation
  • restlessness
  • worsening of convulsions
  • gastrointestinal disturbance
  • tinnitus
  • sleep disorder
  • skin disease
  • increased BUN
  • blood in stool
  • fatigue
  • weakness
  • gait abnormalities
  • decreased libido
  • sleep disorder
  • insomnia
  • ataxia
  • speech disorder
  • sensory disturbances
  • memory impairment
  • attention deficit

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is best kept at room temperature between 1°C and 30°C, avoiding extremes of temperature.

Appearance and packaging

Appearance

White or light yellow round tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.